Pharma BD Deal Intelligence
Pfizer Inc. / NextWave Pharmaceuticals, Inc.
2012 · Acquisition/Merger · $700M · Complete
Announcement Sentiment
71
Positive
Pfizer exercised option (initial $20M Q2 2012 option payment) to acquire NextWave with $255M closing payment plus up to $425M sales milestones. Acquired Quillivant XR, the first FDA-approved once-daily liquid ADHD medication (approved Sept 27 2012).
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Assessment window: 10yr post-close.
Key facts
- Announced Sep 04, 2012
- Closed Nov 28, 2012
- Deal value $700M
- Deal type Acquisition/Merger
- Therapeutic area Attention-deficit/hyperactivity disorder (ADHD)
- Indications Attention-deficit/hyperactivity disorder (ADHD)
- Key assets Quillivant XR (methylphenidate HCl extended-release oral suspension)
- Mechanism CNS stimulant (dopamine/norepinephrine reuptake inhibitor)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals